News Releases

Eurofins_Partner_665x263_2

ImmunoPrecise and Eurofins Partner to Accelerate Antibody Discovery Breakthroughs.

Eurofins Discovery, a company of Eurofins Scientific and a leading international group of laboratories providing a unique range of analytical testing services, has joined forces with ImmunoPrecise. This collaboration complements Eurofins Discovery’s suite of pharmacology services with IPA’s unique antibody discovery portfolio. For IPA customers, it means access to an expanded network of experts on a global scale. This enhances our capacity as a single-source provider, and as an industry leader in end-to-end services.

Read More

ImmunoPrecise Receives CIR – French Tax Credit Approval

We are pleased to offer tax-relief to eligible French companies who engage with us in fundamental and applied research and experimental development activities. We are honored to be able to pass this recognition of our role in research and innovation in scientific antibody discovery in Europe, onto existing and new French partners, in the form of tax relief from the CIR R&D tax credit initiative.

Read More

News Releases

November 30th, 2021

ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program

Polytope™ Reaches Multiple Milestones and IPA Has Commenced Omicron Variant Analysis VICTORIA, BRITISH COLUMBIA (CANADA), November 30, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX…

November 24th, 2021

ImmunoPrecise to present at The Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021

VICTORIA, BRITISH COLUMBIA (CANADA), Novembre 24, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) is presenting at the Benchmark Company’s Discovery One-on-One Virtual…

November 10th, 2021

IPA Announces Resignation of Director

VICTORIA, BRITISH COLUMBIA November 9, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) announced today that Paul Andreola, a member of the…

October 14th, 2021

ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million

VICTORIA, British Columbia, October 13, 2021, – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today…

October 7th, 2021

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre

Multi-target research collaboration leverages ImmunoPrecise’s powerful antibody discovery technologies with the long-standing expertise of Pierre Fabre in immuno-oncology VICTORIA, BRITISH COLUMBIA (CANADA) and CASTRES (FRANCE), October 07, 2021 –…

September 9th, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

VICTORIA, BRITISH COLUMBIA September 9, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development,…

September 8th, 2021

ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation

VICTORIA, BRITISH COLUMBIA September 8, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development,…

September 7th, 2021

ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)

VICTORIA, September 7, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced…

September 3rd, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

The Company to host an earnings conference call via webcast on September 9, 2021, at the close of marketVICTORIA, BRITISH COLUMBIA September 3, 2021 / – IMMUNOPRECISE ANTIBODIES LTD….

August 4th, 2021

ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans

Barry Duplantis, Ph.D., promoted to VP of Client Relations Carla Dahl, appointed to VP of Marketing VICTORIA, BRITISH COLUMBIA August 4, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”…

July 28th, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021

• Total revenue of $17.9 million, up 27% from $14.1 million in fiscal 2020 • Successfully dual listed to Nasdaq Global Market, subsequently raised USD$25 million in bought deal…

July 22nd, 2021

ImmunoPrecise’s PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays

IPA publishes its scientific paper “Cornering an Ever-Evolving Coronavirus: TATX-03, a Fully Human, Synergistic, Multi-Antibody Cocktail Targeting the SARS-CoV-2 Spike Protein with in vivo Efficacy” on bioRxivVICTORIA, BRITISH COLUMBIA…

July 15th, 2021

ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021

The Company to host an earnings conference call via webcast on July 28, 2021, after the close of marketVICTORIA, BRITISH COLUMBIA July 15, 2021 / – IMMUNOPRECISE ANTIBODIES LTD….

June 22nd, 2021

Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform

VICTORIA, BRITISH COLUMBIA, June 22, 2021 / – IMMUNOPRECISE ANTIBODIES LTD (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-service therapeutic discovery and development…

June 17th, 2021

Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction

Treatment with TATX-03a substantially reduced bronchitis and tracheitis severity in preclinical studies-New histopathology data show that the significantly reduced viral load observed after prophylactic and therapeutic treatment with TATX-03a…

June 15th, 2021

Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event

VICTORIA, BRITISH COLUMBIA, June 15, 2021 / – IMMUNOPRECISE ANTIBODIES LTD (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the results from in vitro characterizations investigating…

June 2nd, 2021

ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche

VICTORIA, BRITISH COLUMBIA June 2, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development,…

May 25th, 2021

ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board

VICTORIA, BRITISH COLUMBIA May 25, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development,…

May 20th, 2021

ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing

– Demonstrating what the Company believes to be the first reported in vivo synergistic effects of a multi-antibody (3+) combination treatment – Dr. Ilse Roodink and Dr. Debby Kruijsen…

April 21st, 2021

ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record

VICTORIA, BRITISH COLOMBIA April 21, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development,…

April 8th, 2021

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Potential to Treat Parkinson’s and Other Neurodegenerative DiseasesVICTORIA, BRITISH COLUMBIA April 8, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader…

March 25th, 2021

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern

• Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action • Binds to all tested variants of concern, likely because it targets a site other than…

March 17th, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year

• Immunoprecise and Genmab enter into a technology partnership targeting infectious disease • Immunoprecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-clinical evaluation • Commenced trading on Nasdaq…

March 16th, 2021

ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination TherapyVICTORIA, BRITISH COLOMBIA March 16, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”…

March 4th, 2021

ImmunoPrecise Announces Participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021 (Virtual Conference)

Management to provide corporate update on emerging SARS-CoV-2 variants of concern, (UK, S. African and Brazilian)VICTORIA, British Columbia, March 4, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or…

February 19th, 2021

ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope™ Monoclonal Antibody Cocktail Candidate Against COVID-19

• Treatment of Syrian hamsters with TATX-03, a cocktail of four proprietary monoclonal antibodies directed against distinct regions of the SARS-CoV-2 spike protein, resulted in strong anti-viral effects against…

February 10th, 2021

IPA Announces Closing of Over-Allotment Option Associated with the Recently Completed Bought Deal Offering of Common Shares

VICTORIA, British Columbia, February 10, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development,…

February 8th, 2021

IPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares

VICTORIA, British Columbia, February 8, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development,…

February 3rd, 2021

IPA Increases Previously Announced Bought Deal Offering of Common Shares to $21.7 Million

VICTORIA, BRITISH COLUMBIA February 3, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development,…

February 3rd, 2021

IPA Announces $10.0 Million Bought Deal Offering of Common Shares

VICTORIA, BRITISH COLUMBIA February 3, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development,…

January 7th, 2021

ImmunoPrecise Antibodies Announces Grant of Stock Options

VICTORIA, BC, January 6, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that its board…

January 6th, 2021

ImmunoPrecise Antibodies to Participate in January Conferences

VICTORIA, British Columbia, January 6 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today announced that Dr. Jennifer Bath,…

December 30th, 2020

ImmunoPrecise Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Program

Innovative, novel approach to treat and protect against SARS-CoV-2 using thermoresponsive virus-targeting nanoparticles as an inhalation medicine Program includes development of a heat-sensitive fluorescent SARS-CoV-2 detection assay through patient…

December 23rd, 2020

ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange

VICTORIA, December 23, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (Nasdaq Global Markets: IPA), a leader in full-service, therapeutic antibody discovery and development, is pleased…

December 21st, 2020

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year

• Record Quarterly Revenue of $4,754,545 and Adjusted EBITDA of $795,159 •Announced Strategic Partnership with Mila to Expand AI Capabilities and Functionality of Antibody Development Platform •Advanced Lead Candidates…

December 14th, 2020

ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate

VICTORIA, December 14 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (TSXV:IPA) (OTCQB: IPATD) (FSE:TQB), a leader in full-service, therapeutic antibody discovery and development and LiteVax BV (Oss, the Netherlands),…

December 11th, 2020

ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2

VICTORIA December 11, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATD) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

November 25th, 2020

ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte’s 2020 Technology Fast 500™

VICTORIA, November 25, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

November 23rd, 2020

IPA Selects Polytope™ Formulations for Pre-Clinical Studies

VICTORIA, November 23, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

November 19th, 2020

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

VICTORIA, November 19, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

November 17th, 2020

ImmunoPrecise Antibodies Confirms Effective Date of Share Consolidation

VICTORIA, BC, November 17, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

November 9th, 2020

ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration Statement

VICTORIA, BC, November 9, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

November 4th, 2020

ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq Listing

VICTORIA, BC, November 4, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

November 3rd, 2020

ImmunoPrecise Antibodies and Mila Announce Strategic AI Partnership

VICTORIA, November 3, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

October 27th, 2020

ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products

VICTORIA, October 27, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

October 8th, 2020

IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic Test

Also signs Definitive Commercial Agreement with University of Victoria VICTORIA, October 8, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2),…

October 6th, 2020

IPA’s CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television

VICTORIA, October 6, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

October 5th, 2020

ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends

VICTORIA, October 05, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

September 29th, 2020

ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021

VICTORIA, September 29, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) today announced financial results for its fiscal year 2021 first quarter ended…

September 28th, 2020

IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg Television

VICTORIA, September 28, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

September 28th, 2020

ImmunoPrecise to Present at the Virtual Gravitas Healthcare Investor Day

VICTORIA, September 28, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

September 25th, 2020

ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials

VICTORIA, September 25, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, and LiteVax BV…

September 22nd, 2020

IPA Europe Significantly Expands its Capabilities, Releasing its Second-Generation B Cell Select™

VICTORIA, September 22, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

September 17th, 2020

ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

VICTORIA, September 17, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

September 10th, 2020

ImmunoPrecise Commences Application Process to Dual List on NASDAQ

VICTORIA, September 10, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) ( FSE:TQB2), a provider of best-in-class therapeutic antibody discovery capabilities for…

September 9th, 2020

ImmunoPrecise Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

VICTORIA, September 9, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

September 8th, 2020

IPA CEO to Participate in Virtual Panel: “New Approaches to COVID-19: Hidden Breakthroughs,” on Thursday, September 10th

VICTORIA, September 8, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

September 1st, 2020

ImmunoPrecise Reports Record Revenues and Positive Adjusted EBITDA Fiscal 2020

Reports rapid advancement of COVID-19 antibody programs; combination studies achieve nearly complete neutralization of SARS-CoV-2 VICTORIA, August 31, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE:…

August 13th, 2020

IPA Appoints New York Based Crescendo Communications as Investor Relations and Corporate Communications

VICTORIA, August 13, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a provider of best-in-class therapeutic antibody capabilities announces that it…

July 31st, 2020

IPA’s Human Anti-SARS-CoV-2 Therapeutic Antibodies Demonstrate Synergistic Neutralization

VICTORIA, July 31, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a provider of best-in-class therapeutic antibody capabilities, is pleased to…

July 28th, 2020

IPA Awarded US$1.5M Bioscience Innovation Grant for Coronavirus Research from the North Dakota Department of Agriculture

VICTORIA, July 28, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a best-in-class therapeutic antibody discovery company for the global industry,…

July 20th, 2020

IPA Announces Repayment of Remaining 2018 Debentures and $3,811,205 in Warrant Exercises

VICTORIA, July 20, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

July 13th, 2020

Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA’s Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies

IPA announces discovery of additional, neutralizing antibodies, developed against SARS-CoV-2, discovered using Ligand Pharmaceuticals’ genetically engineered OmniRat® strains producing human antibodies VICTORIA, July 13, 2020 / – IMMUNOPRECISE ANTIBODIES…

June 29th, 2020

IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2

IPA Announces Discovery of Functional Antibodies from Humans and Llama (VHH), Identified Using IPA Phage Display Technology VICTORIA, June 29, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or…

June 22nd, 2020

Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2

Oss, Netherlands, June 22, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), and LiteVax BV (“LiteVax”) (the Netherlands), today announced that…

June 11th, 2020

Recombinant SARS-CoV-2 Proteins Now Available For Research From ImmunoPrecise’s European Subsidiary, UPE

Utrecht, June 11, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA, OTC QB: IPATF, Germany: TQB2) subsidiary U-Protein Express BV (“UPE”) today announced the…

June 4th, 2020

ImmunoPrecise Collaborates with the NIH and Integrated Biotherapeutics to Study the Structural Details of Antibodies with Therapeutic Potential to Treat or Prevent Coronavirus Disease 2019 (COVID-19)

VICTORIA, June 4, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global…

May 27th, 2020

NSERC Awards Grant to Fund Collaboration Between ImmunoPrecise and the University of Victoria for the Generation of a Potential COVID-19 Antibody-Based Test in Canada that can Provide Real-Time Responses

VICTORIA, May 27, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), specialists in custom antibody discovery and development, today announced a collaboration…

May 19th, 2020

ImmunoPrecise Closes Oversubscribed Debenture Financing

VICTORIA, May 15, 2020/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to announce that it has closed its previously announced…

May 15th, 2020

ImmunoPrecise Increases Financing to $2.592 Million

VICTORIA, May 15, 2020/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to announce that it has increased its previously announced…

May 6th, 2020

ImmunoPrecise Antibodies Increases Discovery Capabilities to Help Pinpoint Lead Drug Candidates with Addition of Octet HTX

VICTORIA, May 6, 2020 /- IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global…

April 24th, 2020

ImmunoPrecise Updates on State and Federal Funding

IPA Awarded Grant Focused on Coronavirus and Other Emerging Pathogens Fargo, April 24, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF),…

April 17th, 2020

ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery

We caution that this news release is not making any express or implied claims that we have the ability to eliminate the SARS-CoV-2 virus at this time. We further…

April 15th, 2020

ImmunoPrecise Participates in Public Consensus Statement, from the WHO, on Collaboration for Developing a COVID-19 Vaccine

VICTORIA, April 15, 2020/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) provides an update on its participation and support of global solidarity…

April 14th, 2020

ImmunoPrecise Announces Agreement with Janssen

VICTORIA, BC and CAMBRIDGE, MA, APRIL 14th, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF), a global leader in therapeutic antibody…

April 2nd, 2020

ImmunoPrecise Announces Appointment of Yasmina Noubia Abdiche, Ph.D., as Chief Scientific Officer

VICTORIA, April 2, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the…

March 30th, 2020

ImmunoPrecise’s Artificial Intelligence Partner, EVQLV, Submits First Panel of Optimized Antibody Sequences to Coronavirus for PolyTope™ mAb Therapy Program

We caution that this is still early stage research and development and is not making any express or implied claims that it has the ability to eliminate the SARS-CoV-2…

March 12th, 2020

ImmunoPrecise Announces the Launch of PolyTope mAb Therapy™ to Tackle Coronavirus Pandemic

New Approach Entails a Defined Antibody Combination Targeting Multiple Epitopes and Mechanisms of Viral Evasion VICTORIA, March 12, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX…

March 10th, 2020

ImmunoPrecise Reports Record Quarterly and Nine Month Revenue and Positive Adjusted EBITDA

VICTORIA, March 10, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) today announced financial results for its fiscal year 2020 third quarter ended…

March 9th, 2020

ImmunoPrecise Announces Debt Settlement of Previously Issued Debentures

VICTORIA, March 6, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) announces that it wishes to settle up to $796,875 of…

March 2nd, 2020

ImmunoPrecise Announces Artificial Intelligence Collaboration With EVQLV To Accelerate Vaccine And Antibody Discovery For SARS-CoV-2 Coronavirus

The partnership with the New York-based artificial intelligence company will focus on high-throughput computational antibody design to derive novel leads from ImmunoPrecise’s platforms and accelerate Coronavirus therapeutic antibody discovery…

February 20th, 2020

ImmunoPrecise Launches Coronavirus Vaccine and Therapeutic Antibody Program

VICTORIA, BC, February 20, 2020 – ImmunoPrecise Antibodies Ltd (the “Company”), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, announces its commitment to the development…

January 20th, 2020

ImmunoPrecise integrates SGI-DNA’s benchtop automated DNA printer to accelerate antibody discovery and manufacturing services

VICTORIA, SAN DIEGO, and UTRECHT, January 20, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody…

January 9th, 2020

ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe’s Most Competitive Science Region

VICTORIA and UTRECHT, January 09, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities…

January 6th, 2020

ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 13-16, 2020

VICTORIA, January 6, 2020/- IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) announced today IPA will be in San Francisco during the J.P. Morgan 38th…

December 17th, 2019

ImmunoPrecise Announces Record Quarterly Revenue and Significantly Expands Gross Margins

VICTORIA, December 17, 2019/- IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) announces today that it has released its financial results for the second quarter…

December 3rd, 2019

ImmunoPrecise Announces Annual General Meeting Results

VICTORIA, December 2, 2019 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) announces that all resolutions were passed by the shareholders at…

November 5th, 2019

Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

VICTORIA, November 05, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…

October 18th, 2019

ImmunoPrecise Adopts Shareholder Rights Plan

VICTORIA, October 18, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…

October 14th, 2019

ImmunoPrecise Exhibiting at European Antibody Congress in Basel, October 15-19, 2019

ImmunoPrecise Antibodies will attend the Festival of Biologics held at the Congress Centre, Basel October 15-19th. The Festival of Biologics is a combination of four incredible conferences, the European…

October 3rd, 2019

ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

VICTORIA, October 3, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the…

October 1st, 2019

ImmunoPrecise Antibodies Appoints Biotech Industry Executive Dr. Stefan Lang as Chief Business Officer

VICTORIA, October 1st, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global…

September 24th, 2019

ImmunoPrecise’s Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics

VICTORIA, September 24, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…

September 23rd, 2019

ImmunoPrecise Launches Abthena™ Bispecific Platform And Artemis™ Intelligence Metadata (AIM)

VICTORIA, September 23, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…

August 29th, 2019

ImmunoPrecise Antibodies’ Annual Revenues Increase 100% to $10,926,268 Million

VICTORIA, August 28, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for the year ended April 30,…

August 1st, 2019

ImmunoPrecise’s Wholly Owned Talem Therapeutics Announces the Creation of its Scientific Committee

VICTORIA, August 1, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB PINK: IPATF) announces the launch of its High Value Target Scientific Committee…

July 15th, 2019

ImmunoPrecise Antibodies Announces Immuno-oncology Discovery Collaboration with Entos Pharmaceuticals

VICTORIA, June 12, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF), an industry leader in the discovery of novel, therapeutic monoclonal…

June 26th, 2019

ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform

VICTORIA, June 26, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF), the industry leader in the discovery of novel, therapeutic monoclonal…

May 30th, 2019

ImmunoPrecise’s Diversified Offerings Spark Surge in Requests for use of Nine Different Transgenic Animal Strains on Innovative Service Platforms in B cell Select™️ and DeepDisplay™️

VICTORIA, May 30, 2019 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB PINK: IPATF) announces that its proprietary, high-throughput B cell and phage display platforms have…

April 25th, 2019

ImmunoPrecise Antibodies’ Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt-Surrogate-Fc Growth Factor

VICTORIA, APRIL 25, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) U-Protein Express, a wholly-owned ImmunoPrecise Antibodies subsidiary, in Utrech, Netherlands,…

April 16th, 2019

ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

VICTORIA, April 16, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced today that Jennifer Bath, President and CEO of ImmunoPrecise…

April 11th, 2019

ImmunoPrecise Appoints Andy Nixon to Board of Directors

VICTORIA, April 11, 2019 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that it has appointed Andy Nixon, Vice President of Biotherapeutics Molecule Discovery at…

April 9th, 2019

TetraGenetics and ImmunoPrecise extend collaboration by signing multi-target service agreement for the Discovery of Therapeutic Antibodies

VICTORIA, April 9th, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce the extension of its collaboration with…

April 4th, 2019

ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market

Victoria, British Columbia, Canada, April 03, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that its common shares…

April 4th, 2019

ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics

VICTORIA, April 4, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces it has formed a wholly-owned, Cambridge, Massachusetts-based subsidiary, Talem…

April 2nd, 2019

ImmunoPrecise Launches DeepDisplay(™) Antibody Discovery Platform – ImmunoPrecise Launches Large-Scale Discovery Program with US Pharma Company

VICTORIA, April 2,2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the expansion of their service offerings in therapeutic antibody discovery…

March 28th, 2019

ImmunoPrecise Antibodies Reports Record Q3 2019 Financials Results – Revenues Up 228% For The First 9 Months of Fiscal 2019

VICTORIA, March 27, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for Q3 ended January 31, 2019….

March 15th, 2019

ImmunoPrecise Antibodies Announces Resignation of Jos Raats, as Managing Director of ModiQuest Research BV

VICTORIA, March 15, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today announces that Jos Raats, Ph.D., has resigned from the…

March 1st, 2019

ImmunoPrecise Antibodies Announces DTC Eligibility

VICTORIA, February 28, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that its common shares are now…

February 21st, 2019

ImmunoPrecise Antibodies Receives Subcontract to Produce Rabbit Monoclonal Antibodies

VICTORIA, February 21, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has received a five-year Indefinite Delivery/Indefinite Quantity (ID/IQ) subcontract from…

February 19th, 2019

ImmunoPrecise Antibodies Collaborates with FIND to Help Advance New TB Diagnostic Test

VICTORIA, February 19, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the publication of the results of a research collaboration…

February 14th, 2019

Second US Office for ImmunoPrecise Antibodies, Ltd. in Cambridge, Massachusetts.

VICTORIA, February 14, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced that they have opened a new subsidiary office…

February 5th, 2019

ImmunoPrecise Antibodies Ltd. Increases Antibody Discovery Capabilities with Addition of Integrated Laboratory Equipment for High-throughput Antibody Screening

VICTORIA, February 4th, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced the purchase of its second state-of-the-art Intellicyt® iQue…

January 14th, 2019

ImmunoPrecise Appoints Lisa Helbling as Chief Financial Officer

VICTORIA, January 14, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has appointed Lisa Helbling as…

January 3rd, 2019

ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 7-10, 2019

VICTORIA, January 3, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced today IPA will be in San Francisco during the J.P….

December 26th, 2018

ImmunoPrecise Hires Jason Orloske as Vice President Operations

VICTORIA, Dec. 26, 2018 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce Jason Orloske has accepted the position of Vice President of Operations for…

October 29th, 2018

ImmunoPrecise Antibodies Ltd. Announces Genetic Immunization Platform

Victoria, British Columbia, Canada, October 29, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is excited to expand its immunization services through…

October 15th, 2018

ModiQuest to Offer Ligand’s OmniAb Service in Europe

Victoria, British Columbia, Canada, October 15th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that ModiQuest® Research, an ImmunoPrecise Company, is…

October 9th, 2018

ImmunoPrecise Signs Large Pharma Antibody Development Agreement

Victoria, British Columbia, Canada, October 9th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed…

October 2nd, 2018

ImmunoPrecise Announces Phage Display-Based Antibody Discovery Platforms

Victoria, British Columbia, Canada, October 2nd, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced the addition of in-house and custom phage…

October 1st, 2018

Immunoprecise Antibodies’ Q1 Revenues Increase 386% Over Q1 2017

October 1st, 2018 – Victoria, British Columbia.  IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX Venture: IPA, Pink Sheets: IPATF) today reports its financial results for Q1 ended July 31, 2018.  The…

September 28th, 2018

ImmunoPrecise Closes Oversubscribed Private Placement Raising $9.1m

Victoria, British Columbia, Canada, September 28, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private…

September 21st, 2018

The Centre for Drug Research and Development (CDRD) selected ImmunoPrecise’s Chief Scientific Officer, Dr. Deanna Dryhurst as member of the CDRD Academy Executive Institute

Victoria, British Columbia, Canada, September 21st, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF)  is proud to announce that our CSO, Dr….

August 30th, 2018

ImmunoPrecise and Harbour Antibodies Announce Technology Co-offering Agreement for Next-Generation Fully-human Antibody Discovery

Co-offering Agreement combines ImmunoPrecise’s advanced hybridoma plus B cell screening and sorting services with Harbour Antibodies’ patented H2L2 transgenic mouse platform Victoria, British Columbia, Canada, August 30th, 2018 –…

August 29th, 2018

ImmunoPrecise Antibodies’ Annual Revenues Increase 106% to 5.4 Million

August 29, 2018 – Victoria, British Columbia.  IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX Venture: IPA, Pink Sheets: IPATF) today reports its financial results for the year ended April 30, 2018. …

August 28th, 2018

ImmunoPrecise Increases Private Placement Financing to $7 Million

Victoria, British Columbia, Canada, August 28, 2018 – IMMUNOPRECISE ANTIBODIES LTD.(“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has increased its previously announced non-brokered private placement financing…

August 22nd, 2018

ImmunoPrecise Announces $2 Million Financing

Victoria, British Columbia, Canada, August 22, 2018 – IMMUNOPRECISE ANTIBODIES LTD.(“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it proposes to complete a non-brokered private placement financing of…

August 21st, 2018

ImmunoPrecise Announces the Resignation of Director

Victoria, British Columbia, Canada, August 20, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that Mr. Guy Champagne, has resigned from his position…

July 18th, 2018

ImmunoPrecise Accelerates the Launch of its European, Full-service, B-cell Facility

VICTORIA, July 18, 2018 /CNW/ – To meet global demand, IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) accelerates the launch of its European B-cell facility expansion at its…

June 19th, 2018

ImmunoPrecise Closes Private Placement Financing

Victoria, British Columbia, Canada, June 19, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private…

May 30th, 2018

ImmunoPrecise Increases Private Placement Financing

Victoria, British Columbia, Canada, May 30, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has increased its previously announced non-brokered private…

May 29th, 2018

ImmunoPrecise Announces Private Placement Financing

Victoria, British Columbia, Canada, May 29, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it proposes to complete a non-brokered private placement…

May 25th, 2018

ImmunoPrecise Appoints Jennifer Bath to Board of Directors and Expands Senior Leadership to Further Global Growth

Victoria, British Columbia, Canada, May 24, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, as part of its annual review of management…

May 18th, 2018

ImmunoPrecise Opens U.S. Headquarters in Fargo, North Dakota

Victoria, British Columbia, Canada, May 18, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its U.S. Headquarters in Fargo,…

April 27th, 2018

ImmunoPrecise Opens New Full Service B-Cell Facility

Victoria, British Columbia, Canada, April 27, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its new, innovative full service B-cell…

April 6th, 2018

ImmunoPrecise Announces Oversubscription To Debenture Financing

Victoria, British Columbia, Canada, April 6, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces it has completed a final tranche to its debenture (the “Debentures”)…

April 6th, 2018

ImmunoPrecise Acquires Modiquest Research BV

Immediately Accretive by Adding EBITDA of Approximately C$750,000 with Increased Synergies, Scale and Efficiency Strategic Acquisition Allows ImmunoPrecise to Provide Comprehensive and Next Generation Antibody Therapeutic Discovery Victoria, British…

March 29th, 2018

ImmunoPrecise Antibodies Delivers Record Quarterly Revenue of $1.723 Million and Increases Gross Margins to 54%

March 28, 2018 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX Venture: IPA, OTC PINK: IPATF) today reports its financial results for the third quarter…

March 16th, 2018

ImmunoPrecise Enters Into Definitive Agreement To Acquire Modiquest Research BV

Victoria, British Columbia, Canada, March 16, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has entered into…

February 8th, 2018

ImmunoPrecise Appoints New President and CEO

Victoria, British Columbia, Canada, February 8, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the appointment of Dr. Jennifer Bath, as the new President…

January 27th, 2018

ImmunoPrecise Antibodies Grants Stock Options

VICTORIA, January 27, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSXV:IPA, Pink Sheets:IPATF) reports that, pursuant to the Company’s Stock Option Plan, the Board of Directors has authorized the…

January 18th, 2018

ImmunoPrecise Engages San Francisco Based Lightpath Capital as A Key Partner in its Financing Strategy

Victoria, British Columbia, Canada, January 18, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has engaged LightPath Capital, Inc. (“LightPath”) to act…

December 31st, 2017

ImmunoPrecise Antibodies Reports Second Quarter Results

December 29, 2017 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSXV: IPA, Pink Sheets: IPATF) today reports its financial results for the second quarter ended October 31,…

December 19th, 2017

ImmunoPrecise Adds Scientific Depth To Its Board Of Directors

Victoria, British Columbia, Canada, December 18, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce the appointment of Dr. Robert Burke to…

December 8th, 2017

ImmunoPrecise to Acquire ModiQuest Research BV

Victoria, British Columbia, Canada, December 7, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with…

November 20th, 2017

ImmunoPrecise Realigns Senior Management

Victoria, British Columbia, Canada, November 20, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the realignment of its senior management team as Dr. James…

October 1st, 2017

ImmunoPrecise Antibodies Reports Q1 2018 Results

ImmunoPrecise Develops Humanizing Platforms to Significantly Grow Core Business.Increases Operational Efficiency and Expands Capacity to Scale Quickly September 29, 2017 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (the “Company”)…

September 18th, 2017

Immunoprecise Awarded First Commercial Humanized Antibody Project From Established Biotech Company And Grants Stock Options

Victoria, British Columbia, Canada, September 18, 2017 –  IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has been awarded its first significant…

September 7th, 2017

ImmunoPrecise Antibodies Announces Dr. Oren Beske Joining The Executive Leadership Team and AGM Results

Victoria, British Columbia, Canada, September 7, 2017 –  IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce that Oren Beske, Ph.D. has joined the…

August 29th, 2017

ImmunoPrecise Announces R&D Success Using The OmniAB® Platform to Develop Fully Human Antibodies

Victoria, British Columbia, Canada, August 29, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), announces the Company is now an approved contract research organization (“CRO”)…

August 24th, 2017

ImmunoPrecise Antibodies Reports 2017 Annual Results – Revenues Up 39% Over Fiscal 2016

Victoria, British Columbia, Canada, August 24, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) yesterday reported its financial results for the fourth quarter…

August 24th, 2017

ImmunoPrecise Completes Acquisition of U-Protein and Private Placement of $5.25 Million

Victoria, British Columbia, Canada, August 23, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has completed the acquisition of U-Protein Express BV (“U-Protein”)…

August 11th, 2017

ImmunoPrecise Signs Definitive Agreement with U-Protein

Victoria, British Columbia, Canada, August 11, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, further to its news release dated July 4, 2017, it…

August 3rd, 2017

ImmunoPrecise Announces Expansion Into Humanizing Technologies and Platforms

Victoria, British Columbia, Canada, August 3, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has completed significant steps that enhance…

August 2nd, 2017

ImmunoPrecise Increases Financing to $5.25 Million

Victoria, British Columbia, Canada, August 2, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), in conjunction with its acquisition of U-Protein Express B.V., is pleased to…

July 24th, 2017

ImmunoPrecise Increases Financing to $5.1 Million

Victoria, British Columbia, Canada, July 24, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), in conjunction with its acquisition of U-Protein Express B.V., is pleased to…

July 4th, 2017

ImmunoPrecise To Acquire U-Protein and Announces $4,000,000 Financing

Victoria, British Columbia, Canada, July 4, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with U-Protein…

June 5th, 2017

Immunoprecise Antibodies Opens New Antibody Production Laboratory To Increase Manufacturing Capacity

Victoria, British Columbia, Canada, June 5, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”)(TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce the opening of its new 3,200 square foot state…

April 11th, 2017

Immunoprecise Begins Humanized Antibody Development

Victoria, British Columbia, Canada, April 11, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”)(TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce the launch of a new research initiative.

March 31st, 2017

Immunoprecise Antibodies Reports Q3 2017 Financial Results –Revenues Up 70% For The First Nine Months Of Fiscal 2017

Victoria, British Columbia, Canada, March 30, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), today reports its financial results for the third quarter ended January 31,…

March 9th, 2017

Immunoprecise Adds Dr. David Kroeger As Senior Scientist; New Us Trading Symbol

Victoria, British Columbia, Canada, March 9, 2017 –  IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), a life sciences technology and product company engineering custom antibodies, is…

March 1st, 2017

Immunoprecise Appoints Contact Financial for Investor Relations and Launches New Website For Its Custom Antibody Services

Victoria, British Columbia, Canada, March 1, 2017 –  IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: TQURF), a life sciences technology and product company engineering custom antibodies, announced…

January 23rd, 2017

Immunoprecise Antibodies Issues Letter To Shareholders

Victoria, British Columbia, Canada, January 23, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA), a life sciences technology and product company supplying custom antibodies, today announced that…

Load More